Speaker(s): 

Rosine Richa, PharmD, BCPS.  Resident, Geisinger - has nothing to disclose 

Sidney Dykhuizen, Resident, PharmD, Geisinger - has nothing to disclose 

Moderator(s): 

Sarah Hale, Pharm.D., BCPPS. Director of Pharmacy, Geisinger-has nothing to disclose 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the risks and benefits associated with the timing of anticoagulation initiation following acute ischemic stroke.
• Summarize the study design, key findings, and conclusions of the OPTIMAS trial.
• Evaluate the influence and clinical implications of the OPTIMAS trial on current guidelines and practice patterns.
• Describe the relationship between gabapentinoid use and the increased risk of hip fractures, particularly in older adults.
• Analyze the study's methodology, including the use of data from four linked databases in Australia, for the established association between gabapentinoid use and hip fractures.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brain Simpkins, PharmD, Jessica Milheim, CPhT, and Tiffany Tang, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None